The 340B Rebate Model and Beyond: Three Signals Health Systems Should Prepare For

When Ted Slafsky, 340B Report Publisher and CEO, visited Plenful's San Francisco office, we did what any team tracking 340B closely would do: we sat him down for a fireside chat. Drawing on more than two decades of experience at 340B Health and his current role leading 340B Report, Ted shared his perspective on the revised Rebate Model Pilot, explained the growing burden of 340B reporting, and answered questions about what covered entities should prepare for next.

We've recapped the takeaways that matter most for covered entities heading into a consequential fall.

The Rebate Model is very likely going forward this time

The previous version of the 340B Rebate Model was stopped after a federal court found problems with the process used to establish it. The revised version followed a more extensive stakeholder feedback process.

Ted’s view is that litigation is still likely, but the revised pilot appears more legally durable than the previous version. In other words, covered entities should not assume that another last-minute court decision will eliminate the need to prepare.

That changes the conversation. The Rebate Model is no longer only a policy question. It is an operating-model change that affects how covered entities access 340B pricing.

Even if aspects of the pilot will change, covered entities should begin preparing the underlying data, workflows, and financial visibility needed to manage this new process.

As Ted put it:

"This one is more legally strong, and more likely to withstand litigation. There will be another attempt to try to block the rebate model, but I would say it's unlikely to be successful this time around."

The Rebate Model creates a cash-float problem at scale

The Rebate Model is often described as a claims-submission or reconciliation challenge. But its most significant financial consequence may be the “cash float” it creates.

Under the existing model, covered entities access 340B pricing through the purchasing process. Under a rebate model, they initially pay a higher acquisition price and expect to recover the difference. The time between purchasing the drug and receiving the rebate creates a new working-capital gap.

The financial challenge becomes more complicated when incomplete submission delays the rebate payment timeline, rebate timing varies across manufacturers and drugs and finance teams lack a consolidated view of outstanding cash.

The central question is no longer simply “Did we submit the claim?”. Health systems must also be able to answer:

• How much cash is currently tied up?
• Did we receive the correct amount?
• Which denials or incomplete submissions require action?

Without that visibility, pharmacy and finance teams may struggle to forecast cash flow, validate repayment, and determine whether the organization has been made whole.

340B is entering its “prove it” era

Beyond Rebate, Ted sees a clear direction of regulatory movements: more reporting.

These requirements are emerging in different forms and across different levels of government. Covered entities may increasingly need to report information to state agencies, the federal government, legislators and other external stakeholders. Ted emphasized that 340B policy is increasingly shaped on a state-by-state basis.

This represents a significant shift.

Being a responsible steward of the program will remain essential, but covered entities will also need the data to demonstrate that stewardship consistently and credibly.

For many teams, this information currently lives across multiple claims systems, TPAs, pharmacy platforms, finance tools, and manually maintained spreadsheets. As reporting requirements expand, that approach will become increasingly difficult to sustain. Covered entities will need repeatable and timely reporting infrastructure, consolidated data and a clear audit trail.

For health systems operating in multiple states, this challenge becomes even more complicated given requirements may differ by jurisdiction. It becomes a growing patchwork of requirements that organizations must interpret and operationalize.

Operational readiness starts now

When we asked Ted where Plenful could have the most impact, his answer was direct:

“With the rebate model very likely moving forward, being able to provide as much support in that process will be extremely beneficial to the providers."

Already adopted by health system partners, Plenful's Rebate Management solution streamlines the entire process - from claims identification and automated data submission to rebate validation, reconciliation, and financial oversight.

By accelerating the submission cycle, validating rebate amounts, and flagging delays, Plenful helps reduce avoidable cash float while giving 340B and finance teams a consolidated view of what has been submitted, paid, denied, or remains outstanding.

The rebate model's deadlines are already in motion, and covered entities that prepare now will be the ones who protect their savings when it takes effect.

Want to see what rebate-readiness looks like in practice?

Request a demo to see how Plenful can get your 340B program rebate-ready before the HRSA deadline.